INTRODUCTION {#sec1-1}
============

*Acinetobacter baumannii* is a Gram-negative rod that can be isolated in nature from water and soil. It is becoming an important cause of resistant nosocomial infections as it was found to be a causative agent in ventilator associated pneumonia, central line associated blood stream infection, catheter associated urinary tract infection and surgical site infection. Community acquired infections such as community acquired pneumonia has also been seen. Even though this bacterium has been well reported in literature to cause hospital acquired infections, its association with post-endoscopic retrograde cholagiopancreatography (ERCP) bacteremia and sepsis has not been well studied.

*A. baumannii* is an unusual cause of post-ERCP bacteremia and as shown in our patient, the infection may be fatal. This case emphasizes the need for appropriate precautions and consideration of unusual pathogens in patients with bacteremia or sepsis post-ERCP.

CASE REPORT {#sec1-2}
===========

The present case report is about an 85-year-old female patient with a history of diverticular disease, hypertension, left hip arthroplasty and gout was admitted to our hospital with a 1-week history of jaundice, lethargy, confusion and multiple episodes of falls. She denied any fever or abdominal pain.

Her initial vital signs were: Blood pressure 92/68 mmHg, temperature 98.0°F and pulse rate 86/min. Icteric sclera was noted. The rest of the physical examination including neurological system, skin, throat, chest and abdomen was normal. Murphy\'s sign was absent.

Significant laboratory findings included white blood cell count, 13,400/μL (4-11/μL) (differential counts of 81% neutrophils, 8% lymphocytes, 6% monocytes); hemoglobin, 13.8 g/dL (12-15.3 g/dL); platelet count, 268,000/mL (150-450/mL); blood urea nitrogen 39 mg/dL (6-26 mg/dL); creatinine 1.57 mg/dL (0.5-1 mg/dL); total bilirubin 6.2 mg/dL (0-1 mg/dL); aspartate aminotransferase 248 U/L (0-32 U/L); alanine aminotransferase 185 U/L (0-40 U/L); and alkaline phosphatase 617 U/L (35-104 U/L).

A computed tomography scan of the abdomen \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\] revealed a 1.8 cm obstructing stone in a distal common bile duct. The patient was empirically started on intravenous levofloxacin and metronidazole. Two days after her admission, she underwent ERCP. The procedure was terminated due to profuse bleeding following papillotomy. The stone was not extracted. Initial blood cultures did not grow any pathogen.

![Transverse section from a Computed tomography scan of the abdomen showing a stone in the common bile duct. Arrow pointing to the stone](AJM-4-37-g001){#F1}

![Coronal section from a Computed tomography scan of the abdomen showing the same stone in the common bile duct. Arrow pointing to the stone](AJM-4-37-g002){#F2}

At 4 days after her hospitalization, the patient underwent a second ERCP \[[Figure 3](#F3){ref-type="fig"}\]. Pieces of stones were extracted and a stent was placed in the common bile duct. One day later, the patient became lethargic and developed a fever of 100.8F. The next morning, the patient deteriorated further with a blood pressure of 76/46 mmHg, pulse rate of 104 beats/min, respiratory rate of 25 breaths/min and oxygen saturation was 94% on 6 L nasal cannula with other clinical evidence of shock believed to be secondary to sepsis.

![Endoscopic retrograde cholagiopancreatography showing a defect representing a stone in the common bile duct](AJM-4-37-g003){#F3}

Antibiotics were switched to intravenous meropenem 500 mg twice daily with intravenous levofloxacin 750 mg. The next day, blood cultures revealed Gram-negative rods.

On day 9, she required intubation and mechanical ventilation for respiratory failure with the addition of maximum vasopressor support for refractory shock. Percutaneous cholecystostomy was performed on day 10 and 5 mL of thick brown fluid was aspirated.

5 out of 5 sets of blood cultures as well as culture of biliary fluid grew *A. baumannii*, resistant to almost all antibiotics including piperacillin/tazobactam, meropenem and levofloxacin. Intravenous tigecycline 50 mg every 12 h was added and parenteral colistin 75 mg every 12 h replaced meropenem based on the final sensitivity reports. Blood cultures drawn after the administration of colistin remained sterile. However, the patient did not recover from septic shock. After discussing the goals of care, her family opted for withdrawing medical management and pursuing comfort measures instead.

DISCUSSION {#sec1-3}
==========

Bacteremia as a complication of ERCP has been well studied and reported in the literature. It is considered a severe complication that can be fatal if not promptly recognized and treated.\[[@ref1]\] In a retrospective study done in Korea by Kwak *et al.*,\[[@ref1]\] patients going for ERCP with no prior signs of infection were selected and investigated for the development of post-procedure bacteremia. 70 patients developed post-ERCP bacteremia mostly due to *Enterobacteriaceae* and those represented 3.1% of the study population. This study also suggested that elevated serum alkaline phosphatase and a prior liver transplant are independent risk factors for post-ERCP bacteremia.

Another study done by Anderson *et al.*\[[@ref2]\] showed that blood stream infections were detected in 46 out of the 2052 patients who got ERCP, calculating incidence of 2.24%. The most common organisms were *Enterobacteriaceae* (29%) followed by Enterococci (22%).

Early and appropriate antibiotic coverage in bacteremic patients improves mortality. The antibiotic regimen in cases of post-ERCP bacteremia should cover Gram-negative and anaerobic bacteria, however, there is no consensus on the best regimen and antibiotics should be modified based on the culture results.

*Acinetobacter* bacteremia was reported previously in a 46-year-old female as a complication of ERCP.\[[@ref3]\] However, the identified species in that case was ursingii.

*A. baumannii* is a Gram-negative bacillus that is known to affect those with compromised immune system. However, it is becoming an important nosocomial infection causing sepsis and pneumonia in ventilated and non-ventilated patients.\[[@ref4][@ref5]\] More attention has been given to this bacterium following the emergence of multi drug resistant (MDR) clones.\[[@ref6]\]

Treatment of *A. baumannii* starts empirically with a broad-spectrum cephalosporin, a combination of beta-lactam/beta-lactamase inhibitor or a carbapenem.\[[@ref7]\] When the sensitivity of the bacteria becomes available, more directed therapy should be initiated. In MDR cases, colistin, Polymyxin B or Tigecycline can be used.\[[@ref8][@ref9]\] Antibiotic therapy was tailored based on culture and susceptibility reports, but the outcome in our patient was poor.

There have been some studies looking at measures to reduce the risk of post-ERCP bacteremia and sepsis but the results were somehow controversial. In a study done in Texas, Gentamycin incorporated into the contrast material was successful in reducing the rates of post-ERCP bacteremia.\[[@ref10]\] In another study, antibiotics were used parenterally prior to ERCP but failed to produce any significant change in the incidence of bacteremia.\[[@ref11]\]

CONCLUSION {#sec1-4}
==========

Bacteremia and sepsis are potentially fatal complications of ERCP. We believe that physicians should be aware of *A. baumannii* as a possible cause of post-ERCP bacteremia. There is an increase in the rate of the MDR strains, which require empiric broad spectrum antibiotics. Treatment is best directed by the culture and sensitivity of body fluids and delay in treatment is associated with worse outcome.

**Source of Support:** Nil

**Conflict of Interest:** None declared.
